Accepted at 10:39 a.m. Dec, 08, 2023 by Ahmed7
Author: kirbysama
Co-authors: Ahmed7
Related Note: 1497203886624 1
Rationale for change

Memory aid linking the relevant cell type to a reasonable pronunciation for the drug natalizumab.

NATE-alizumab affects CD8+ cells.

Specifically, writing this out as N-EIGHT-alizumab rather than the alternative NATE-alizumab makes the connection and the pronunciation more obvious to learners whose primary language is not English, since the pronunciation of the name "Nate" may be less obvious than "Eight" which also has the obvious numerical connotation.

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy
Empty field
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::03_Therapeutic_antibodies::01_Autoimmune_disease_therapy::*Natalizumab #AK_Step1_v12::#SketchyPharm::Immunology-&-Biochemistry-Pharmacology::Immuno-suppressives::General-Immunotherapy #AK_Step1_v12::#Pixorize::05_Neuroanatomy::14_Neurological_Disorders::06_Multiple_Sclerosis_(MS) #AK_Step1_v12::#Bootcamp::Neurology::10_Demyelinating_Diseases::02_Multiple_Sclerosis #AK_Step2_v12::#B&B::10_Neuro::04_Demyelinating_Disorders::01_Multiple_Sclerosis::Extra #AK_Step2_v12::#SketchyNeurology::11_Demyelinating_&_Inflammatory_Disease::01_CNS_Demyelinating_&_Inflammatory_Disease::02_Multiple_Sclerosis:_Evaluation_&_Management #AK_Step2_v12::#AMBOSS::fo0kYS #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::03_Therapeutic_antibodies #AK_Step1_v12::#OME::PreClinical::Immunology #AK_Step1_v12::#Bootcamp::Immunology::13_Transplant_Rejection::08_Biologic_Immunotherapy #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::^Other::^EXPN